202 related articles for article (PubMed ID: 36914088)
41. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
Scaggs Huang F
J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
[TBL] [Abstract][Full Text] [Related]
42. Persistent but dysfunctional mucosal SARS-CoV-2-specific IgA and low lung IL-1β associate with COVID-19 fatal outcome: A cross-sectional analysis.
Ruiz MJ; Siracusano G; Cottignies-Calamarte A; Tudor D; Real F; Zhu A; Pastori C; Capron C; Rosenberg AR; Temperton N; Cantoni D; Liao H; Ternette N; Moine P; Godement M; Geri G; Chiche JD; Annane D; Cramer Bordé E; Lopalco L; Bomsel M
Front Immunol; 2022; 13():842468. PubMed ID: 36248831
[TBL] [Abstract][Full Text] [Related]
43. Comparison of anti-SARS-CoV-2 IgG and IgA antibody responses post complete vaccination, 7 months later and after 3rd dose of the BNT162b2 vaccine in healthy adults.
Rastawicki W; Juszczyk G; Gierczyński R; Zasada AA
J Clin Virol; 2022 Jul; 152():105193. PubMed ID: 35660747
[TBL] [Abstract][Full Text] [Related]
44. Validation of a combined ELISA to detect IgG, IgA and IgM antibody responses to SARS-CoV-2 in mild or moderate non-hospitalised patients.
Cook AM; Faustini SE; Williams LJ; Cunningham AF; Drayson MT; Shields AM; Kay D; Taylor L; Plant T; Huissoon A; Wallis G; Beck S; Jossi SE; Perez-Toledo M; Newby ML; Allen JD; Crispin M; Harding S; Richter AG
J Immunol Methods; 2021 Jul; 494():113046. PubMed ID: 33775672
[TBL] [Abstract][Full Text] [Related]
45. Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine.
Pitcovski J; Gruzdev N; Abzach A; Katz C; Ben-Adiva R; Brand-Shwartz M; Yadid I; Ratzon-Ashkenazi E; Emquies K; Israeli H; Haviv H; Rapoport I; Bloch I; Shadmon R; Eitan Z; Eliahu D; Hilel T; Laster M; Kremer-Tal S; Byk-Tennenbaum T; Shahar E
Vaccine; 2022 Feb; 40(8):1098-1107. PubMed ID: 35078662
[TBL] [Abstract][Full Text] [Related]
46. Rapid increase in salivary IgA and broad recognition of spike protein following SARS-CoV-2 vaccination.
Ota K; Sakai H; Sasaki D; Mitsumoto-Kaseida F; Sakamoto K; Kosai K; Hasegawa H; Takazono T; Izumikawa K; Mukae H; Tun MMN; Morita K; Yanagihara K
Virus Res; 2024 Jan; 339():199294. PubMed ID: 38056502
[TBL] [Abstract][Full Text] [Related]
47. Decline of humoral immune responses after natural SARS-CoV-2 infection can be efficiently reversed by vaccination.
Oktelik FB; Yilmaz V; Gelmez MY; Akdeniz N; Pamukcu C; Sutlu T; Kose M; Tuzun E; Deniz G
Can J Microbiol; 2022 Aug; 68(8):543-550. PubMed ID: 35852365
[TBL] [Abstract][Full Text] [Related]
48. Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2.
Fujigaki H; Yamamoto Y; Koseki T; Banno S; Ando T; Ito H; Fujita T; Naruse H; Hata T; Moriyama S; Takahashi Y; Suzuki T; Murakami T; Yoshida Y; Yagura Y; Oyamada T; Takemura M; Kondo M; Iwata M; Saito K
Microbiol Spectr; 2022 Feb; 10(1):e0118121. PubMed ID: 35044205
[TBL] [Abstract][Full Text] [Related]
49. The level of protective post-vaccination antibodies in NIPH-NIH employees after administration of Pfizer vaccine against COVID-19.
Rastawicki W; Płaza K
Przegl Epidemiol; 2021; 75(1):3-13. PubMed ID: 34328282
[TBL] [Abstract][Full Text] [Related]
50. Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2.
Planchais C; Fernández I; Bruel T; de Melo GD; Prot M; Beretta M; Guardado-Calvo P; Dufloo J; Molinos-Albert LM; Backovic M; Chiaravalli J; Giraud E; Vesin B; Conquet L; Grzelak L; Planas D; Staropoli I; Guivel-Benhassine F; Hieu T; Boullé M; Cervantes-Gonzalez M; Ungeheuer MN; Charneau P; van der Werf S; Agou F; ; ; Dimitrov JD; Simon-Lorière E; Bourhy H; Montagutelli X; Rey FA; Schwartz O; Mouquet H
J Exp Med; 2022 Jul; 219(7):. PubMed ID: 35704748
[TBL] [Abstract][Full Text] [Related]
51. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
52. Serum IgG anti-SARS-CoV-2 Binding Antibody Level Is Strongly Associated With IgA and Functional Antibody Levels in Adults Infected With SARS-CoV-2.
Ye X; Angelo LS; Nicholson EG; Iwuchukwu OP; Cabral de Rezende W; Rajan A; Aideyan LO; McBride TJ; Bond N; Santarcangelo P; Rayford YJ; Ferlic-Stark L; Fragoso S; Momin Z; Liu H; Truong K; Lopez B; Conner ME; Rice AP; Kimata JT; Avadhanula V; Piedra PA
Front Immunol; 2021; 12():693462. PubMed ID: 34691016
[TBL] [Abstract][Full Text] [Related]
53. The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines.
Chan RWY; Liu S; Cheung JY; Tsun JGS; Chan KC; Chan KYY; Fung GPG; Li AM; Lam HS
Front Immunol; 2021; 12():744887. PubMed ID: 34712232
[TBL] [Abstract][Full Text] [Related]
54. Longitudinal IgA and IgG Response, and ACE2 Binding Blockade, to Full-Length SARS-CoV-2 Spike Protein Variants in a Population of Black PLWH Vaccinated with ChAdOx1 nCoV-19.
Smith M; Kwatra G; Izu A; Nel A; Cutland C; Ahmed K; Baillie V; Barnabas S; Bhorat Q; Briner C; Lazarus E; Dheda K; Fairlie L; Koen A; Madhi S; Blackburn JM
Viruses; 2023 Feb; 15(2):. PubMed ID: 36851662
[TBL] [Abstract][Full Text] [Related]
55. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.
Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972
[TBL] [Abstract][Full Text] [Related]
56. Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders.
Sauerwein KMT; Geier CB; Stemberger RF; Rossmanith R; Akyaman H; Illes P; Fischer MB; Eibl MM; Walter JE; Wolf HM
J Allergy Clin Immunol; 2023 Apr; 151(4):922-925. PubMed ID: 36463978
[TBL] [Abstract][Full Text] [Related]
57. COVID-19 Severity, Cardiological Outcome, and Immunogenicity of mRNA Vaccine on Adult Patients With 22q11.2 DS.
Pulvirenti F; Mortari EP; Putotto C; Terreri S; Fernandez Salinas A; Cinicola BL; Cimini E; Di Napoli G; Sculco E; Milito C; Versacci P; Agrati C; Marino B; Carsetti R; Quinti I
J Allergy Clin Immunol Pract; 2023 Jan; 11(1):292-305.e2. PubMed ID: 36280136
[TBL] [Abstract][Full Text] [Related]
58. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
Front Immunol; 2021; 12():690698. PubMed ID: 34276681
[TBL] [Abstract][Full Text] [Related]
59. Trajectory of Spike-Specific B Cells Elicited by Two Doses of BNT162b2 mRNA Vaccine.
Ciabattini A; Pastore G; Lucchesi S; Montesi G; Costagli S; Polvere J; Fiorino F; Pettini E; Lippi A; Ancillotti L; Tumbarello M; Fabbiani M; Montagnani F; Medaglini D
Cells; 2023 Jun; 12(13):. PubMed ID: 37443740
[TBL] [Abstract][Full Text] [Related]
60. Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination.
Taus E; Hofmann C; Ibarrondo FJ; Gong LS; Hausner MA; Fulcher JA; Krogstad P; Kitchen SG; Ferbas KG; Tobin NH; Rimoin AW; Aldrovandi GM; Yang OO
Front Immunol; 2023; 14():1100594. PubMed ID: 36860850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
